SK Chemical-developed hemophilia treatment applied for EMA approval

Published: 2015-12-24 13:59:57

Updated: 2015-12-24 14:00:44

A hemophilia treatment, developed by the SK Chemicals’ own technology, is about to target the foreign advanced markets.

On the 23^rd, SK Chemicals(CEO Man-hoon Park) announced CSL, a partnering company, completed the European Medicines Agency’s(EMA) commercialization approval application of ‘NBP601(CSL626),’ a new biomedicine of hemophilia treatment. It has already complete the FDA’s commercial...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.